Great Swedish innovations: Eye treatment became a feather in Pharmacia’s cap

From complicated and sometimes risky surgery to a routine procedure. Pharmacia’s injectable Healon revolutionised the field of eye surgery - and is considered by us one of the most important contemporary Swedish innovations in the field of medicine.

Outsourcing som strategi för ökad trovärdighet

Idag, torsdag, pågår Life Science Swedens event Pharma Outsourcing på Stockholm Waterfront. Under en av föreläsningarna jämfördes för- och nackdelar med att ta sig an uppgifter och problem internt med att köpa in tjänster.

Dags för ”ett av våra mest efterfrågade möten”

He is zooming in on topical preparations

According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting approval for its new GMP facility.

Flyttar gränser för gen- och cellterapi

”Vi är bra på att vara innovativa och flytta gränser inom gen- och cellterapi och den här studien symboliserar det på ett tydligt sätt”, säger Evelina Vågesjö, vd för Ilya Pharma, om den kliniska studie som företaget startar nästa år.

Han går på djupet med topikala beredningar

Topikala produkter inom läkemedelsutveckling är en växande marknad, enligt Zelmics vd David Sagna, och för att hålla jämna steg med utvecklingen väntar företaget på godkännande för sin nya GMP-anläggning.

Swedish breakthrough in Alzheimer’s: “We can finally present great data”

Treatments for Alzheimer’s disease are currently among the hottest topics in drug development. Two Swedish research companies with high ambitions and successes in the field participated in Bioscience 2022 conference at Life City in Hagastaden, Stockholm.

"Are we doing business the wrong way around in the Life Science Sector?"

For the past 50 years we have created solutions for problems that we thought would solve the problems. Pharmaceuticals have created big block buster drugs which were great for that time but now we realise that these drugs were in fact only tested in white men and certainly not for patients who are older who are taking a number of medications.

Svenskt genombrott inom Alzheimers i fokus på Bioscience: "Äntligen har vi fina data"

Behandlingar mot Alzheimers sjukdom hör till det hetaste just nu inom läkemedelsutveckling. Två svenska forskningsbolag med stora ambitioner – och framgångar – inom området deltog vid tisdagens konferens Bioscience 2022 på Life City i Hagastaden.

Lucy Robertshaw startar mötesplats om svensk life science

Lucy Robertshaw, som modererat flera event åt Life Science Sweden, lanserar en sajt på engelska om svensk life science.

“We aim to be a start-up company with an academic spirit”

Chronic pain and Alzheimer’s are two diseases that plague many people worldwide and seem impossible to cure. However, Huddinge-based company Alzecure is working on developing drugs for both conditions.

”Riktlinjer följs inte alltid som man skulle önska”

Det behövs kontaktytor mellan vårdprofession, patienter och företag, konstaterar Penilla Gunther och Mattias Hellström i en tv-intervju från Fokus Patient Event.

“We need to keep investing in research and innovation”

Jenni Nordborg has worked for just over four years to highlight life science in Sweden. Her mandate as national coordinator ends in December 2022. ““Life sciences has been a long-term priority of governments since many years and I have no doubt that the ambitions will be strong going forward”, says Jenni Nordborg.

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.

FOKUS Patient turns international

FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.

Life Science-podden: The perfect moment for an IPO

When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?

Swedish-Danish meeting at Medicon Village: “One of the most important life science congresses”

For the eleventh year, The Future of Swedish and Danish Life Science was held on Wednesday, and the event continues to function as a connecting link between the life science sectors of both countries. This year’s event attracted nearly 450 visitors.

Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?

Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.

Stort engagemang på möte om medicinteknik: "Vi vet att lösningarna finns"

Hur ska alla innovativa medicintekniska lösningar inom diagnostik och behandling kunna nå patienten – utan att snubbla på alla juridiska, tekniska och formella hinder på vägen? Det var ämnet för ett välbesökt event i Göteborg på onsdagen.

Sweden is heavily criticised for not ordering Covid vaccine

Valneva and the EU Commission have entered into an agreement for 1.25 million doses of the company’s Covid vaccine, but Sweden has not placed an order.

Amorphous materials take centre stage when Orexo develops new formulations

Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s Research and Development Manager Robert Rönn.

BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”

For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leaving the hub. This is the message from the biohub’s CEO Magnus Björsne in an interview, in which he also highlights a study that points out that companies with a high degree of interaction with other companies achieve greater success.

Bioventurehubs vd: ”Företag som interagerar mycket når större framgång”

Astra Zenecas Bioventurehub kan för första gången sedan starten rekrytera nya bolag då några av hyresgästerna växt väsentligt och nu lämnar hubben. Det berättar biohubbens vd Magnus Björsne i en intervju där han också lyfter fram en studie som pekar på att företag som interagerar mycket med andra bolag når större framgångar.

Ny metod för mikroskopi öppnar genväg till nya läkemedel

Forskare vid Chalmers har utvecklat en helt ny mikroskopiteknik för att kunna studera de minsta biologiska partiklarna i sitt naturliga tillstånd – och därmed öppna vägar för snabbare utveckling av nya läkemedel och vaccin.